Start with an identity match, not an ingredient name
This reference sets out a comparison method for readers who have found a longevity-related study and want to know whether a supplement label describes the same intervention. It does not assess whether any intervention works, whether a study is persuasive, or whether a product should be used. Those are separate questions. The explainers on reading a clinical trial, surrogate endpoints and absolute versus relative risk address other parts of that appraisal.
The central distinction is simple. A trial tests a specified intervention in specified people, for a defined period and against a comparator. A label identifies a consumer product and supplies only the information required or chosen for its presentation. The same broad ingredient name can cover materially different preparations. It can also conceal differences that matter to interpretation, including chemical form, plant part, standardisation, delivery format, co-ingredients and the amount consumed each day.
Do not begin from the assumption that a label is a practical version of the trial. Begin with the narrower question: can the label's disclosed information establish a match to the intervention described in the study? If the answer is no, the appropriate result is unresolved, rather than matched or unmatched. Unresolved is useful. It records that the evidence cannot be carried from the paper to the labelled product on the available information.
A shared front-label ingredient name is a lead for comparison, not evidence that the research intervention and retail product are the same.
This method also separates intervention identity from evidence quality. A carefully conducted trial may still be irrelevant to a product that does not match it. Conversely, an apparent label match does not make a small, short or poorly controlled study decisive.
What a label can disclose, and what it usually cannot
Read the full label rather than the front claim. The ingredients panel, nutrition or supplement information, suggested use and any qualifying notes may reveal the material's stated form and quantity. A label may name a compound, a botanical species, an extract, a mineral salt, a serving size and an amount per serving. It may also state the number of servings suggested per day. These are the raw materials for comparison, but they do not automatically describe the intervention well enough to reproduce it.
For a compound, the relevant distinction may be between the named compound and a particular salt, ester, complex or other formulation. The weight of the named material is not always the same as the weight of the active moiety. For a botanical, the relevant distinctions can include species, plant part, extraction solvent, extract ratio and standardised constituents. An extract described as a ratio indicates a relationship between starting plant material and extract, but it does not by itself establish the quantity of any particular constituent. A standardisation statement may be more informative, provided the constituent and basis are specified.
Labels also commonly report an amount per serving rather than an amount per day. A study may report its intervention as a total daily amount, sometimes divided across administrations. A reader must therefore distinguish the capsule, scoop or tablet from the stated serving, and the stated serving from the labelled number of servings per day. Neither calculation should be extended beyond what the label actually says.
Some labels use proprietary blends. Where a blend gives only a total weight for several components, the quantity of each component is not disclosed. That makes a dose-level comparison with a study impossible for those components. Other commonly absent details include manufacturing specifications, measured composition, stability over shelf life, contaminant testing, bioavailability data and the precise composition of a batch used in research. Their absence does not prove a defect. It does mean the label cannot establish those facts.
Read the trial intervention as a complete description
A study report should be read for the intervention actually administered, not for the shorthand used in its title or abstract. The methods section, protocol where available, trial registration record and supplementary material can each contain details omitted from the headline description. Start by recording the intervention name exactly as reported. Then record its form, amount, schedule, duration, route and whether it was used alone or with other interventions.
The unit matters. Human trials may report an amount per day, per administration, per kilogram of body weight, or another defined basis. An amount per kilogram is individualised to each participant's body size. It cannot be assumed to correspond to a fixed amount on a label. A daily amount is easier to compare only if the chemical or botanical form, dosing schedule and formulation also align. A study that divides an amount through the day is not automatically interchangeable with a once-daily labelled serving.
Formulation can affect exposure even where the nominal ingredient is similar. The trial may use a specific preparation, delivery system or controlled product that is not identified by a retail label. It may also use a purified substance while a label describes a whole extract, or vice versa. A multi-component study intervention tests the combination as used. It does not isolate each component's contribution, and a product containing one shared component is not a match.
Record the study population and context too. Participants may have a particular age range, health status, dietary pattern or medication use. The trial may impose adherence checks, restrictions or supervision that do not exist outside research. These features are not label properties, but they limit what it means to call a product comparable. Identity matching is necessary before evidence is transferred, but it is never sufficient for a conclusion about outcomes in a different group.
Animal doses are not labels written in another unit
Animal studies can identify mechanisms, toxicology signals or questions suitable for later human research. They do not provide a direct shopping comparison. A study in an animal species reports an intervention given under species-specific experimental conditions. Converting a number by body weight alone is not a valid way to identify a human equivalent intake. Species differ in body size, metabolism, absorption, distribution, elimination, diet, lifespan and the way an intervention is administered.
Researchers sometimes use body-surface-area scaling to derive a human-equivalent dose for early translational work. This is a scientific convention for a particular purpose, not a consumer conversion rule. It does not establish that the resulting amount has the same exposure, effect or safety profile in people. It cannot correct for a different chemical form, different formulation or a route of administration that a label does not reproduce.
The study route deserves particular attention. An intervention supplied in feed, water, injection or a laboratory formulation is not necessarily comparable with an oral retail product. The reported amount may reflect concentration in feed or water rather than verified individual intake. Animals may also receive an intervention throughout a larger proportion of their lifespan than would be practical or studied in people. These differences are part of the result, not incidental details to discard.
For this title's evidence grading, animal findings can support biological plausibility or justify interest in human research. They do not establish a human healthspan outcome, and they cannot verify that a label matches a tested human intervention. Keep the species, route and dosing basis visible in notes. If there is no human trial using a sufficiently described intervention, the label-to-study comparison ends there.
The four checks before calling a label a study match
Use the following rule in order. It is designed to prevent a familiar error: finding one matching word, then overlooking every other difference. The result is not a recommendation or a safety assessment. It is a classification of how far the disclosed label can be compared with a particular study intervention.
| Check | What to compare | Result if information differs or is missing |
|---|---|---|
| 1. Material identity | Exact compound, salt, ester, complex, botanical species, plant part, extract or standardised constituent. | Do not treat a broad ingredient name as a match. Mark identity unresolved or different. |
| 2. Daily exposure | Amount per serving multiplied only by the label's stated servings per day, against the trial's reported daily or body-weight-based amount. | A per-serving figure alone is insufficient. A body-weight-based study cannot be reduced to a fixed label comparison without study-specific information. |
| 3. Formulation and companions | Delivery form, release characteristics, excipients where relevant, and every active component in the studied intervention. | A shared component does not match a combination or a distinct formulation. |
| 4. Research context | Human or animal study, route, duration, population, comparator and trial conditions. | Do not carry findings across species, routes or populations as though the label resolves those gaps. |
Decision rule: Call a product-study comparison “described match” only when all four checks are supported by sufficiently specific disclosed information and the study is in people. If any check is unknown, call it “unresolved”. If a material, amount, formulation, route or intervention composition differs, call it “not the same intervention”. These labels describe comparability, not effectiveness, quality or suitability.
A proprietary blend will often stop check 2 because individual quantities are unavailable. An extract ratio without a corresponding description in the paper may stop check 1 or 3. A study reporting only an animal dose stops check 4 for human comparison. These are not technicalities. Each one changes the meaning of the claim that a product is “based on” a study.
How this method fits an evidence grade
Comparability is a gate before grading, rather than a grade in itself. This title's grading apparatus asks what design and outcome evidence are needed for a claim about healthspan. A high evidence grade is no recommendation. Before that apparatus is applied to a product-related question, first establish what intervention the evidence concerns. A study cannot strengthen a claim about a product that it did not test, or whose identity cannot be established from the label.
Keep two records. The first is an intervention-match note using the four checks. The second is an evidence note covering design, population, outcome, duration, comparator, uncertainty and relevance. This separation prevents label detail from being mistaken for clinical evidence, and prevents an impressive trial citation from being mistaken for proof of product equivalence.
For example, a label may disclose a specific daily amount yet provide no basis for matching the trial formulation. That is a partially described label, not a partially proven outcome. Equally, a trial may use a well-characterised intervention but measure a short-term surrogate endpoint. Strong identity matching does not overcome limitations in the endpoint. The separate explainer on surrogate endpoints addresses why a measurable change may not answer a healthspan question.
When discussing a paper, use precise wording: “the study tested”, “the label states”, “the match is unresolved”, or “the interventions differ”. Avoid wording that merges these propositions into one. This makes uncertainty visible to readers and preserves the distinction between evidence appraisal and consumer inference.
Limits of this reference
This method concerns the comparison of publicly disclosed supplement-label information with a study intervention. It does not assess manufacturing quality, contamination, legality, advertising compliance, authenticity, interactions, contraindications or individual risk. It cannot verify contents that are not disclosed or independently measured. It is also not a substitute for the UK rules discussed in this title's supplement-regulation explainer.
It does not apply cleanly to prescription medicines, medical foods, compounded preparations, devices or interventions delivered by clinicians. Those categories have different documentation, regulatory and clinical considerations. Nor does it determine whether a person should start, stop or combine any substance. Questions involving symptoms, diagnosed conditions, pregnancy, breastfeeding, prescribed medicines or planned procedures require a clinician or pharmacist who can consider the individual context.
The method is deliberately conservative. “Unresolved” does not mean a product is ineffective, unsafe or inferior. “Not the same intervention” does not mean either intervention has no effect. It means that one cannot use that particular study as direct evidence for that labelled product. Similarly, a described match does not establish benefit, safety, quality or relevance to a reader's goals.
Finally, labels and formulations can change. Compare the version in hand with the study record being cited, and record the date of access in personal notes. If the trial intervention, label form or daily-use instruction cannot be determined, do not fill the gap with an assumed conversion or a claim of equivalence.